

Expert Forum Session 3

HER2 Crossroads:
Navigating Molecular
Diagnostic Pitfalls and
Possibilities



2025.11.21 | Fri | 19:00-20:50

TIME	TOPIC	SPEAKER	MODERATOR
19:00-19:10	Opening & Introduction	張基晟 醫師 中山附醫	
19:10-19:40	The HER2 Trail: Tracking Trends and Targetable Populations (Mutation, Amplification & Overexpression)	Dr. Gerrina Ruiter Early Drug Development Center , Netherlands Cancer Institute (NKI)	張基晟 醫師 中山附醫
19:40-20:00	Q&A		
20:00-20:40	Panel Discussion	張基晟 醫師 中山附醫 林聖皓 醫師 彰化基督教醫院 涂智彥 醫師 中國附醫 李純慧 醫師 成大醫院 王業翰 醫師 輔大附醫 李健逢 醫師 奇美醫院	楊宗穎 醫師 臺中榮總
20:40-20:50	Summary & Closing	楊宗穎 醫師 臺中榮總	

REGISTRATION



Dr. Gerrina Ruiter

**Early Drug Development Center ,
Netherlands Cancer Institute (NKI)**

Dr. Gerrina Ruiter is a pulmonologist specializing in thoracic oncology at the Netherlands Cancer Institute in Amsterdam, The Netherlands. She works in the Departments of Thoracic Oncology and Clinical Pharmacology, with a focus on early clinical drug development and phase I studies.

After completing her Ph.D. on pulmonary hypertension, Dr. Ruiter transitioned her research focus to lung cancer, driven by her passion for developing personalized treatment strategies. Her clinical expertise covers the full spectrum of thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, and neuroendocrine tumors. She has particular expertise in HER2-altered NSCLC and has been actively involved in presenting emerging data on novel targeted therapies, including zongertinib, at major international meetings such as WCLC 2025.

Dr. Ruiter has authored more than 20 publications with over 1,000 citations, as evidenced by her contributions to the field through peer-reviewed publications and international conference presentations.

